ow dose vitamin K to improve therapeutic quality control of oral anticoagulant treatment: a randomized double-blind placebo controlled trial.
Completed
- Registration Number
- NL-OMON25820
- Lead Sponsor
- Trombosestichting Nederland
- Brief Summary
J Thromb Haemost. 2007 Oct;5(10):2043-8. Epub 2007 Jul 31.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1. Patients treated at the Leiden anticoagulation clinic with an indication for long-term oral anticoagulant therapy using the vitamin K antagonist phenprocoumon;
2. Age between 18 and 80 years;
Exclusion Criteria
1. Treatment by a medical specialist for liver failure;
2. Haemo- or peritoneal dialysis;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Quality of anticoagulant treatment;<br /><br>2. Expressed as time in therapeutic range.
- Secondary Outcome Measures
Name Time Method 1. Number of INRs in therapeutic range;<br /><br>2. Bleeding and thromboembolic complications.